デフォルト表紙
市場調査レポート
商品コード
1586123

心臓再同期療法デバイス市場:製品別、エンドユーザー別-2025年~2030年の世界予測

Cardiac Resynchronization Therapy Devices Market by Product (Cardiac Resynchronization Therapy Defibrillators, Cardiac Resynchronization Therapy Pacemakers), End-User (Ambulatory Surgery Centers, Hospitals & Cardiac Centers) - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 182 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.95円
心臓再同期療法デバイス市場:製品別、エンドユーザー別-2025年~2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心臓再同期療法デバイス市場は、2023年に49億8,000万米ドルと評価され、2024年には53億6,000万米ドルに達すると予想され、CAGR 7.70%で成長し、2030年には83億8,000万米ドルに達すると予測されています。

心臓再同期療法(CRT)装置は、電気インパルスを通じて心臓の効率と収縮の調整を改善することで、心不全の管理に極めて重要な役割を果たしています。CRTの必要性は、心臓関連疾患、特に心不全の有病率が高まっていることに起因しており、これは世界の高齢化、座りがちなライフスタイルの増加、肥満率の上昇によって悪化していることが多いです。これらの機器は主に、従来の治療法では不十分であることが判明した場合に、重度の心臓機能不全に苦しむ人々を治療するために使用されます。ワイヤレスCRTやマルチポイントペーシングなどの技術進歩により、最終用途は病院、診療所、心臓専門医療センターにまで広がっています。

主な市場の統計
基準年[2023] 49億8,000万米ドル
予測年[2024] 53億6,000万米ドル
予測年[2030] 83億8,000万米ドル
CAGR(%) 7.70%

市場の洞察によれば、重要な成長要因は、心血管疾患に対する意識の高まりと、それに伴う予防ヘルスケアへの注力です。技術革新と有利な償還政策もCRTデバイスの採用を後押ししています。しかし、高額な機器コスト、潜在的な副作用、厳しい規制当局の承認プロセスなどの制約が、市場成長の課題となる可能性があります。さらに、これらの機器を操作する熟練した専門家の不足が、特に発展途上地域での普及を制限しています。潜在的なビジネスチャンスは、戦略的提携を通じて市場範囲を拡大し、人工知能やビッグデータ解析の台頭を活用して機器の機能や患者の転帰を改善することにあります。

機器のコスト削減、バッテリー寿命の向上、患者のコンプライアンス改善に焦点を当てた調査への投資は、技術革新を刺激することができます。また、低侵襲の埋め込み技術を開拓することで、市場の受容を拡大することができます。患者中心の医療が優先される中、遠隔モニタリングと個別化治療のためのスマート技術の統合は、引き続き極めて重要です。市場の競争は激しく、技術革新とヘルスケア支出の増加によって急速に進化しています。アクセシビリティと患者教育のギャップに対処することで、大きな配当が得られる可能性があります。この領域で事業を展開する企業は、技術革新、戦略的パートナーシップ、新興市場での事業展開に注力することで、市場の課題を克服しつつ、大きな成長機会を得ることができると思われます。

市場力学:急速に進化する心臓再同期療法デバイス市場の主要市場インサイトを公開

心臓再同期療法デバイス市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 心血管疾患および標的疾患の発生率の増加
    • 世界の集中治療室数の増加
    • 先進国および新興諸国におけるヘルスケア支出の急増
  • 市場抑制要因
    • CRTデバイスの高コスト
  • 市場機会
    • 心臓再同期療法デバイスにおける先端技術の統合
    • 新しく革新的なCRTデバイスのイントロダクション
  • 市場の課題
    • 心臓再同期療法デバイスを操作する熟練者の不足

ポーターの5つの力:心臓再同期療法デバイス市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:心臓再同期療法デバイス市場における外部からの影響の把握

外部マクロ環境要因は、心臓再同期療法デバイス市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心臓再同期療法デバイス市場における競合情勢の把握

心臓再同期療法デバイス市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心臓再同期療法デバイス市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心臓再同期療法デバイス市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨心臓再同期療法デバイス市場における成功への道筋を描く

心臓再同期療法デバイス市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 心血管疾患および標的疾患の発生率の増加
      • 集中治療室の数が世界中で増加
      • 先進国と新興諸国におけるヘルスケア費の急増
    • 抑制要因
      • CRTデバイスの高コスト
    • 機会
      • 心臓再同期療法デバイスにおける先進技術の統合
      • 新しい革新的なCRTデバイスのイントロダクション
    • 課題
      • 心臓再同期療法デバイスを操作する熟練した人材の不足
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 心臓再同期療法デバイス市場:製品別

  • 心臓再同期療法除細動器
  • 心臓再同期療法ペースメーカー

第7章 心臓再同期療法デバイス市場:エンドユーザー別

  • 外来手術センター
  • 病院と心臓センター

第8章 南北アメリカの心臓再同期療法デバイス市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋の心臓再同期療法デバイス市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの心臓再同期療法デバイス市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • 市場シェア分析2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • Biotronik AG
  • Boston Scientific Corporation
  • EBR Systems, Inc.
  • General Electric Company
  • Japan Lifeline Co., Ltd.
  • Koninklijke Philips N.V.
  • Livanova PLC
  • MEDICO S.R.L.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Microport Scientific Corporation
  • Osypka Medical GmbH
  • Siemens AG
  • St. Jude Medical, LLC
図表

LIST OF FIGURES

  • FIGURE 1. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET RESEARCH PROCESS
  • FIGURE 2. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY PACEMAKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY HOSPITALS & CARDIAC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CARDIAC RESYNCHRONIZATION THERAPY DEVICES MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-433AB1DC2896

The Cardiac Resynchronization Therapy Devices Market was valued at USD 4.98 billion in 2023, expected to reach USD 5.36 billion in 2024, and is projected to grow at a CAGR of 7.70%, to USD 8.38 billion by 2030.

Cardiac Resynchronization Therapy (CRT) devices play a pivotal role in managing heart failure by improving the heart's efficiency and coordination of its contractions through electrical impulses. The necessity for CRT devices stems from the growing prevalence of heart-related disorders, especially heart failure, which is often exacerbated by an aging global population, increasing sedentary lifestyles, and rising obesity rates. These devices are primarily used to treat individuals suffering from severe heart dysfunction when conventional therapies prove insufficient. The end-use scope extends to hospitals, clinics, and specialized heart care centers, driven by technological advancements like wireless CRTs and multi-point pacing.

KEY MARKET STATISTICS
Base Year [2023] USD 4.98 billion
Estimated Year [2024] USD 5.36 billion
Forecast Year [2030] USD 8.38 billion
CAGR (%) 7.70%

Market insights reveal that significant growth factors are the rising awareness of cardiovascular diseases and the subsequent focus on preventive healthcare. Technological innovations and favorable reimbursement policies also boost the adoption of CRT devices. However, limitations like high device costs, potential side effects, and the stringent regulatory approval process can pose challenges to market growth. Additionally, a lack of skilled professionals to operate these devices limits their widespread adoption, especially in developing regions. Potential opportunities lie in expanding market reach through strategic collaborations and leveraging emerging artificial intelligence and big data analytics to refine device functionalities and patient outcomes.

Investment in research focusing on reducing device costs, enhancing battery life, and improving patient compliance can stimulate innovation. Developing minimally invasive implantation techniques can also widen market acceptance. With patient-centered care becoming a priority, integrating smart technologies for remote monitoring and personalized therapy remains crucial. The nature of the market is competitive and rapidly evolving, driven by technological breakthroughs and increasing healthcare expenditure. Addressing the gaps in accessibility and patient education could yield substantial dividends. For businesses operating in this domain, a focus on technological innovation, strategic partnerships, and expanding in emerging markets could unlock substantial growth opportunities while overcoming prevailing market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cardiac Resynchronization Therapy Devices Market

The Cardiac Resynchronization Therapy Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of cardiovascular and target diseases
    • Growing number of intensive care units globally
    • Surge in healthcare expenditure across developed and developing countries
  • Market Restraints
    • High cost of CRT devices
  • Market Opportunities
    • Integration of advanced technologies in cardiac resynchronization therapy devices
    • Introduction of new and innovative CRT devices
  • Market Challenges
    • Lack of skilled personnel to operate cardiac resynchronization therapy devices

Porter's Five Forces: A Strategic Tool for Navigating the Cardiac Resynchronization Therapy Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cardiac Resynchronization Therapy Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cardiac Resynchronization Therapy Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cardiac Resynchronization Therapy Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cardiac Resynchronization Therapy Devices Market

A detailed market share analysis in the Cardiac Resynchronization Therapy Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cardiac Resynchronization Therapy Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cardiac Resynchronization Therapy Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cardiac Resynchronization Therapy Devices Market

A strategic analysis of the Cardiac Resynchronization Therapy Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Resynchronization Therapy Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Biotronik AG, Boston Scientific Corporation, EBR Systems, Inc., General Electric Company, Japan Lifeline Co., Ltd., Koninklijke Philips N.V., Livanova PLC, MEDICO S.R.L., Medtronic PLC, Merit Medical Systems, Inc., Microport Scientific Corporation, Osypka Medical GmbH, Siemens AG, and St. Jude Medical, LLC.

Market Segmentation & Coverage

This research report categorizes the Cardiac Resynchronization Therapy Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cardiac Resynchronization Therapy Defibrillators and Cardiac Resynchronization Therapy Pacemakers.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Cardiac Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of cardiovascular and target diseases
      • 5.1.1.2. Growing number of intensive care units globally
      • 5.1.1.3. Surge in healthcare expenditure across developed and developing countries
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of CRT devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of advanced technologies in cardiac resynchronization therapy devices
      • 5.1.3.2. Introduction of new and innovative CRT devices
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled personnel to operate cardiac resynchronization therapy devices
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Resynchronization Therapy Devices Market, by Product

  • 6.1. Introduction
  • 6.2. Cardiac Resynchronization Therapy Defibrillators
  • 6.3. Cardiac Resynchronization Therapy Pacemakers

7. Cardiac Resynchronization Therapy Devices Market, by End-User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgery Centers
  • 7.3. Hospitals & Cardiac Centers

8. Americas Cardiac Resynchronization Therapy Devices Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cardiac Resynchronization Therapy Devices Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cardiac Resynchronization Therapy Devices Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Biotronik AG
  • 3. Boston Scientific Corporation
  • 4. EBR Systems, Inc.
  • 5. General Electric Company
  • 6. Japan Lifeline Co., Ltd.
  • 7. Koninklijke Philips N.V.
  • 8. Livanova PLC
  • 9. MEDICO S.R.L.
  • 10. Medtronic PLC
  • 11. Merit Medical Systems, Inc.
  • 12. Microport Scientific Corporation
  • 13. Osypka Medical GmbH
  • 14. Siemens AG
  • 15. St. Jude Medical, LLC